KalVista's Sebetralstat Advances Toward Potential Approval for Hereditary Angioedema
核心洞察
KalVista Pharmaceuticals' NDA for sebetralstat, an oral plasma kallikrein (搜索) inhibitor, has been accepted by the FDA for on-demand treatment of hereditary angioedema (搜索) (HAE) attacks.
The FDA has set a PDUFA goal date of June 17, 2025, for sebetralstat, marking a significant step toward potential market availability.
A pediatric clinical trial (KONFIDENT-KID) has been initiated to evaluate an orally disintegrating tablet formulation of sebetralstat in children aged 2 to 11 years.
KalVista Pharmaceuticals is making strides in its efforts to bring sebetralstat, a novel oral plasma kallikrein (搜索) inhibitor, to market for the on-demand treatment of hereditary angioedema (搜索) (HAE) attacks. The U.S. Food and Drug Administration (FDA) has accepted KalVista's New Drug Application (NDA) for sebetralstat, setting a Prescription Drug User Fee Act (PDUFA) goal date of June 17, 2025.
This acceptance signifies a crucial step toward providing a new treatment option for HAE patients. Ben Palleiko, CEO of KalVista, expressed enthusiasm about the progress, stating, "We are excited about the steady progress we’ve made over the last few months including the most recent acceptance of our NDA by FDA and the EMA’s validation of our MAA."
Regulatory Milestones and Expansion
In addition to the FDA acceptance, the European Medicines Agency (EMA) has validated the submission of the Marketing Authorization Application (MAA) for sebetralstat. KalVista plans to file for approval in the UK, Japan, and other countries later in 2024, aiming for a first commercial launch in June 2025. The company is also engaging with the Access Consortium to streamline regulatory collaboration across countries.
Pediatric Clinical Trial
KalVista has initiated a pediatric clinical trial (KONFIDENT-KID) using an orally disintegrating tablet (ODT) formulation of sebetralstat. This trial will enroll approximately 24 children, aged 2 to 11 years, across multiple countries in North America, Europe, and Asia. If approved, sebetralstat would be the first oral, on-demand treatment option for this young population.
Financial Overview
KalVista's financial results for the first fiscal quarter ended July 31, 2024, show research and development expenses of $26.6 million, compared to $19.3 million for the same period in the prior fiscal year. General and administrative expenses were $17.6 million, compared to $9.8 million in the prior year. The company's cash, cash equivalents, and marketable securities totaled $174.3 million on July 31, 2024.
Clinical Data and Publication
Data from the phase 3 KONFIDENT trial of sebetralstat was published in the New England Journal of Medicine and presented at the European Academy of Allergy and Clinical Immunology Congress 2024 (EAACI). The KONFIDENT trial demonstrated the efficacy of sebetralstat in treating HAE attacks, providing robust evidence supporting its potential approval.